Navigation Links
Denosumab increases bone density, cuts fracture risk in prostate cancer survivors
Date:8/11/2009

Twice-yearly treatment with denosumab, a new targeted therapy to stop bone loss, increased bone density and prevented spinal fractures in men receiving androgen-deprivation therapy for prostate cancer. The report from an international research study, the first to document reduced fracture risk in men receiving the hormone-blocking treatment, will appear in the August 20 New England Journal of Medicine and is receiving early online release.

"Androgen-deprivation therapy is the standard treatment for men with locally advanced, recurrent and metastatic prostate cancer; but many active men who have been successfully treated for their cancer develop debilitating bone fractures as a result," says Matthew Smith, MD, PhD, of the Massachusetts General Hospital (MGH) Cancer Center, who led the study as part of the Denosumab HALT Prostate Cancer Study Group. "The results of this study should be critically important in improving the quality of life of thousands of prostate cancer survivors."

About one third of the two million prostate cancer survivors in the U.S. currently receive androgen-deprivation therapy, which blocks the release of testosterone. Several medications used to treat osteoporosis, including the drugs called bisphosphonates, have been shown to reduce androgen-deprivation-related bone loss in men in earlier small clinical studies, but none of those trials were adequate to demonstrate reduced fracture risk. Denosumab a fully human monoclonal antibody that blocks the action of osteoclasts, the cells that break down bone in the normal process of bone remodeling is also being investigated to prevent fractures in women with osteoporosis. The current study was a Phase 3 trial supporting the application for FDA approval filed by Amgen Inc., the primary sponsor of the NEJM report.

Men undergoing androgen-deprivation therapy for nonmetastatic prostate cancer were enrolled at 156 centers in North America and Europe and randomly assigned to receive injections of either denosumab or a placebo every six months for three years. Participants were also instructed to take daily calcium and vitamin D supplements during the study period.

Among the more than 900 participants who completed the study, denosumab significantly increased bone density at all the monitored sites including the lumbar spine, total hip and femoral neck and reduced new vertebral fractures by 62 percent. Bone density at the radius, one of the bones in the forearm, also increased in the treatment group, an improvement not seen with other osteoporosis drugs. Few adverse events were associated with treatment, and there were no reports of osteonecrosis of the jaw, a problem reported in some patients taking bisphosphonates.

"Denosumab is an important new therapy to prevent painful fractures in prostate cancer survivors," Smith says. "An ongoing clinical trial will also evaluate whether denosumab prevents spread of prostate cancer to bone, the most common site of metastases in men with this disease." Smith is an associate professor of Medicine at Harvard Medical School.


'/>"/>

Contact: Katie Marquedant
kmarquedant@partners.org
617-726-0337
Massachusetts General Hospital
Source:Eurekalert

Related medicine news :

1. Amgens Denosumab and Eli Lillys Forteo/Forsteo Will Drive Robust Annual Growth in the Osteoporosis Drug Market From 2013 to 2018
2. Carefxs New Referral Management Solution Increases Hospital Referral Volume, Enhances Collaboration Among Specialists, PCPs and Patients
3. Blue Cross Blue Shield of Michigan, Michigan Attorney General and Michigan Office of Financial and Insurance Regulation Near Agreement on Rate Increases on Under Age 65 Individual Products
4. Summer heat increases risk of amniotic fluid level deficiency, Ben-Gurion University study reveals
5. Physicians Level of Concern for H1N1 Swine Flu Steadily Increases
6. Bankers Life and Casualty Company Increases Support of Alzheimers Association to More Than $329,000
7. Universal Health Services, Inc. Reports Significant Increases In 2009 Second Quarter and Six-Month Earnings, Raises Full Year Guidance
8. Smoking increases potential for metastatic pancreatic cancer
9. American CareSource Holdings Increases ACS Networks Convenience and Quality With MinuteClinic Signing
10. FRC: Ryan Bill Increases Abortion While Claiming to Reduce Need for Abortion
11. Transforming Care Together Initiative at Charleston Area Medical Center Increases Time Spent on Patient Care at the Bedside
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2016)... , ... May 05, 2016 , ... ... Drago presented a talk highlighting the organization’s successful Care Transitions program ... , The talk was titled “Minimizing Costs in the Post-Acute Environment Through Effective ...
(Date:5/5/2016)... CA (PRWEB) , ... May 05, 2016 , ... The ... the Year, Derek Pittman, along with his university coaching staff. Together they bring their ... with separate sessions run for youth players ages 5-13, and high school players. Session ...
(Date:5/5/2016)... (NEW YORK, New York) , ... (PRWEB) May 05, 2016 , ... ... partnership with healthcare talent acquisition startup, HireNurses, on the eve of National Nurses ... for job seeking nurses and healthcare employers. With their enrollment into the Talent Tech ...
(Date:5/5/2016)... ... 05, 2016 , ... United Collection Bureau, Inc. (UCB) announces Sarah Clark as ... years of experience within the healthcare revenue cycle industry. With a primary focus of ... Patient Financial Services at Spectrum Health. While at Spectrum Health, Clark helped Spectrum achieve ...
(Date:5/5/2016)... ... ... Institute will celebrate its three-year anniversary on May 14 by giving away a free ... May. To date, the Lung Institute has treated over 2,000 people at their five clinics ... the success of this treatment and to the patients who refuse to give up,” says ...
Breaking Medicine News(10 mins):
(Date:5/4/2016)... Yissum Research Development Company ... that it had signed an exclusive world-wide licensing and ... novel protein degradation and immunomodulatory drugs for cancer and ... candidates representing first-in-class therapy for hematologic and solid malignancies. ... The novel technology was developed by Yinon ...
(Date:5/4/2016)... , May 4, 2016 ... of the  "Global Acute Ischemic Stroke Market ... to their offering.       (Logo: ... Global Acute Ischemic Stroke Market and Competitive ... Acute Ischemic Stroke pipeline products, Acute Ischemic ...
(Date:5/3/2016)... Global Insulin Needles Industry ... key companies and supported with 272 tables and ... on the current state of the Insulin Needles ... including definitions, classifications, applications and industry chain structure. ... the international market including development history, competitive landscape ...
Breaking Medicine Technology: